Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Guiyang
Clinical trial register · China

Clinical Trials in Guiyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 26 Chengdu 23 Changsha 19 Guangzhou 18 Shanghai 16
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Sun Yat-sen University9 The Affiliated Hospital Of Guizhou Medical University6 Huashan Hospital5 Peking Union Medical College Hospital4 Institute of Hematology & Blood Diseases Hospital, China4 Merck Sharp & Dohme LLC4 argenx3 Janssen Research & Development, LLC3 Sichuan Baili Pharmaceutical Co., Ltd.3 Guizhou Medical University3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Guizhou Provincial People's Hospital3 Peking University First Hospital3 BeOne Medicines3 Sanofi3 Pfizer3 Jiangsu HengRui Medicine Co., Ltd.2 Sichuan University2 Eli Lilly and Company2 Liu Shu2 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 Boehringer Ingelheim2 Epygenix2 Fudan University2 Abbisko Therapeutics Co, Ltd2 Shenzhen Ausa Pharmed Co.,Ltd2 Hoffmann-La Roche2 Novartis Pharmaceuticals2 West China Second University Hospital2 Beijing Tiantan Hospital2 Chinese Academy of Sciences2 Santen Pharmaceutical Co., Ltd.2 Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.2 Haisco Pharmaceutical Group Co., Ltd.2 Alexion Pharmaceuticals, Inc.2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2 Second Xiangya Hospital of Central South University1 Children's Hospital of Chongqing Medical University1 Epizyme, Inc.1 Shanghai Pharmaceuticals Holding Co., Ltd1 Beijing Friendship Hospital1 RenJi Hospital1 Sixth Affiliated Hospital, Sun Yat-sen University1 Second Affiliated Hospital of Nanchang University1 Shanghai Hongdian Medical CO., LTD1 The Children's Hospital of Zhejiang University School of Medicine1 Jinling Hospital, China1 ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.1 Nanjing Leads Biolabs Co.,Ltd1 Chiang Mai University1 Beijing Jishuitan Hospital1 Guizhou Sinorda Pharmaceutical Co., Ltd.1 Xuhua Duan1 Shanghai Henlius Biotech1 Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1 Hinova Pharmaceuticals Inc.1 Summit Therapeutics1 Eisai Co., Ltd.1 Children's Hospital of Fudan University1 United Innomed(Shanghai) Limited1 Ningbo Newbay Technology Development Co., Ltd1 Excyte Biopharma Ltd1 ADARx Pharmaceuticals, Inc.1 Southern Medical University, China1 Shanghai Junshi Bioscience Co., Ltd.1 Evopoint Biosciences Inc.1 Guangdong Association of Clinical Trials1 Ruijin Hospital1 Yan Zhang1 West China Hospital1 Beletalent (Zhuhai) Pharmaceutical Co., Ltd1 Novo Nordisk A/S1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1 Amgen1 Beijing University of Chinese Medicine1 Shanghai Xinzhi BioMed Co., Ltd.1 Suzhou Genhouse Bio Co., Ltd.1 Candid Therapeutics1 Shanghai Pulmonary Hospital, Shanghai, China1 Tasly Pharmaceutical Group Co., Ltd1 Tongji Hospital1 Shanghai Jiaolian Drug Research and Development Co., Ltd1 Hutchmed1 Xuanwu Hospital, Beijing1 Gilead Sciences1 Ascentage Pharma Group Inc.1 Xinghua Liu1 Shenzhen NewDEL Biotech, Co., Ltd1 Oupushifang Pharmaceutical Technology Co., Ltd.1 Arrowhead Pharmaceuticals1 JIANGSU SHENMING Medical Technology CO., Ltd1 MicroPort NeuroTech Co., Ltd.1 Shenzhen Kexing Pharmaceutical Co., Ltd.1 Boston Scientific Corporation1 Akeso1 Beijing InnoCare Pharma Tech Co., Ltd.1 Nanjing Minova Pharmaceutical Co., Ltd.1 Suzhou Sanegene Bio Inc.1 Sun Yat-Sen University Cancer Center1 Shanghai Eye Disease Prevention and Treatment Center1 China-Japan Friendship Hospital1 Clear sponsor filter
Target enrolment
to

Trials with a site in Guiyang

2 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2027-01-11
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Rows per page Showing 1–2 of 2
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/guiyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2 of those studies with a site in Guiyang that also match the filters currently applied.

How many clinical trials are recruiting in Guiyang?

1 of the 2 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guiyang), 2 studies
PhaseStudiesRecruitingShare
Phase 321100%

Most active sponsors

Lead sponsors with the most studies (Guiyang)
Lead sponsorStudiesRecruiting
Boehringer Ingelheim21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.